Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI0002h CAR-T for relapsed or refractory multiple myeloma
ACTRN12625001031459Phase 2Not yet recruiting
- Sponsor
- Cell and Tissue Therapies WA
- Start
- Feb 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARI0002h in multiple myeloma (MM), sponsored by Cell and Tissue Therapies WA. Primary endpoints: Efficacy of ARI0002h and Safety of ARI0002h. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ARI0002h
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12625001031459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001031459.